DOI: 10.1128/AAC.00825-20
Article Information
PubMed
Published By
History
- Received April 28, 2020
- Returned for modification May 25, 2020
- Accepted August 2, 2020
- Published online September 21, 2020.
Copyright & Usage
Copyright © 2020 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (August 05, 2020).
- You are viewing the most recent version of this article.
Author Information
- Natalia Fintelman-Rodriguesa,i,
- Carolina Q. Sacramentoa,i,
- Carlyle Ribeiro Limai,
- Franklin Souza da Silvab,i,
- André C. Ferreiraa,c,i,
- Mayara Mattosa,i,
- Caroline S. de Freitasa,i,
- Vinicius Cardoso Soaresa,
- Suelen da Silva Gomes Diasa,
- Jairo R. Temerozod,e,
- Milene D. Mirandaf,
- Aline R. Matosf,
- Fernando A. Bozzag,h,
- Nicolas Carelsi,
- Carlos Roberto Alvesb,
- Marilda M. Siqueiraf,
- Patrícia T. Bozzaa and
- Thiago Moreno L. Souzaa,i
- aLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil
- bLaboratório de Biologia Molecular e Doenças Endêmicas, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil
- cUniversidade Iguaçu, Nova Iguaçu, Rio de Janeiro, Brazil
- dLaboratório de Pesquisas sobre o Timo, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil
- eNational Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil
- fLaboratório de Vírus Respiratório e do Sarampo, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil
- gInstituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil
- hInstituto D’or de Pesquisa e Ensino, Rio de Janeiro, Rio de Janeiro, Brazil
- iNational Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil
- Address correspondence to Thiago Moreno L. Souza, tmoreno{at}cdts.fiocruz.br.
Natalia Fintelman-Rodrigues, Carolina Q. Sacramento, and Carlyle Ribeiro Lima contributed equally to this work. The order of the first three authors was determined alphabetically, excluding the first given name.
Citation Fintelman-Rodrigues N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, Ferreira AC, Mattos M, de Freitas CS, Cardoso Soares V, da Silva Gomes Dias S, Temerozo JR, Miranda MD, Matos AR, Bozza FA, Carels N, Alves CR, Siqueira MM, Bozza PT, Souza TML. 2020. Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production. Antimicrob Agents Chemother 64:e00825-20. https://doi.org/10.1128/AAC.00825-20.
